Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexCelebrex cardiac problems are among the most dangerous side effects associated with Celebrex use. Celebrex is a COX-2 non-steroidal anti-inflammatory (NSAID) prescription painkiller produced by Pfizer. Celebrex was approved to treat the pain associated with osteoarthritis, rheumatoid arthritis, surgical recovery, menstrual cramps, and other forms of chronic and acute pain. Celebrex is also the only COX-2 selective NSAID approved to treat familial adenomatous polyposis.
Evidence of Celebrex cardiac problems first became a concern after the recall of a similar drug called Vioxx. Results from a clinical trial indicated that patients taking Vioxx for eighteen months were twice as likely to suffer cardiac problems or a stroke, as compared to the trial’s control group. As a result of this information, Vioxx’s maker decided to voluntarily pull Vioxx of the shelves.
After the September 2004 Vioxx recall, there was a growing concern about the cardiovascular safety of all COX-2 selective painkillers. Pfizer consistently claimed that these deadly heart and stroke problems were unique to Vioxx and therefore patients and doctors should not be concerned about Celebrex cardiac problems.
In December 2004 Pfizer publicly announced that a Celebrex cancer study was suspended as a result of findings indicating serious Celebrex cardiac problems. A three year study conducted by the National Cancer Institute was designed to measure the effectiveness of Celebrex in treating colorectal polyps. After preliminary findings were collected, the study was stopped short of completion because of serious Celebrex cardiac problems.
Trial participants who had been taking 400 milligrams of Celebrex each day were found to be 2.5 times more likely to suffer Celebrex cardiac problems or stroke than the participants in the control group. Participants taking 800 milligrams were 3.4 times more likely to suffer Celebrex cardiac problems or stroke compared to those participants taking a dummy pill.
Despite this evidence of Celebrex cardiac problems, Pfizer has made no indication that they plan to pull Celebrex off the shelves. Since December 2004, the FDA has ordered Pfizer to pull all Celebrex commercials, stating that the company “overstated the benefits and underestimated the risks” associated with Celebrex use. Several researchers and medical experts have cautioned consumers about Celebrex cardiac problems and advised them to seek alternatives until these risks can be further assessed.
If you are concerned about Celebrex cardiac problems, you may wish to speak to your physician in greater detail. Possible symptoms of Celebrex cardiac problems may include: anxiety, paleness, irregular heart beat, shortness of breath, fainting, sweating, nausea, chest pain, and lightheadedness.
If you or a loved one has experienced Celebrex cardiac problems, you may wish to contact a legal professional who can determine your legal rights and options in a case.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...